MY PICK IS ELN

[New-born baby]

HHmmmm

I see a triple top on the 6mth daily is what I see. And it's sitting right at the neck of a pretty good looking SHS (the head isn't higher than the L shoulder of course). If the neckline breaks, that is fuel to push it down to 6.00 and under all that nice vol by price that's been building. Money flow is bad and pops have been sold. I am bearish on it.

I'll do a full chart later, I'm walkin' out the door.

HHHmmmmm--Let's see:
ELN's resistance is $8--a triple top of resistance! How pretty in a bear market!
Current price is $7.83. Not so far away.
Next supports are $6.50 and $6.00, then all the way down to $4.50. Nice possible reward with minimum risk. Isn't that what Spike likes? Risk .17 vs. a minimum target gain of $1.33. Let's see: that's . . . that's . . . Runner, can you give me a count off of your parachute strings? Yeah, that's right: 7.8235294 to 1 reward/risk ratio. Thanks.
And the market due for a ten cent bounce before it takes a jump off the high dive . . . .
What more--what more I say--what more do you want, Webs, to short this dog?

[Websman]

HHHmmmmm--Let's see:
ELN's resistance is $8--a triple top of resistance! How pretty in a bear market!
Current price is $7.83. Not so far away.
Next supports are $6.50 and $6.00, then all the way down to $4.50. Nice possible reward with minimum risk. Isn't that what Spike likes? Risk .17 vs. a minimum target gain of $1.33. Let's see: that's . . . that's . . . Runner, can you give me a count off of your parachute strings? Yeah, that's right: 7.8235294 to 1 reward/risk ratio. Thanks.
And the market due for a ten cent bounce before it takes a jump off the high dive . . . .
What more--what more I say--what more do you want, Webs, to short this dog?

Oh yea of little faith...

[New-born baby]

Webs . . . she's arrived

Webs,
She's arrived. That beautiful princess: ELN!!!

(music, maestro!)

[Runner]

HHHmmmmm--Let's see:
ELN's resistance is $8--a triple top of resistance! How pretty in a bear market!
Current price is $7.83. Not so far away.
Next supports are $6.50 and $6.00, then all the way down to $4.50. Nice possible reward with minimum risk. Isn't that what Spike likes? Risk .17 vs. a minimum target gain of $1.33. Let's see: that's . . . that's . . . Runner, can you give me a count off of your parachute strings? Yeah, that's right: 7.8235294 to 1 reward/risk ratio. Thanks.
And the market due for a ten cent bounce before it takes a jump off the high dive . . . .
What more--what more I say--what more do you want, Webs, to short this dog?

NB, if you’ll look at my chart of ELN notice the red line has crossed the pink, thus creating the green line to slip down and away from the blue line. This simply indicates a mixed bag of Trix. Now I’ve also set this into the future and I’ve fine tunned my para chord and it looks like a double flat running into a wall. What this foretells is more of the same is in store for ELN. If the moon lines up just right however, this could end the double flat causing a huge wave of fresh buyers into the market.

[kingofthehill]

Elan (Buy, Closing Price $7.83); Tysabri: judgement day approaching.
Analyst: Ian Hunter T +353-1-6410498 E [email protected]
We have issued a 35-page report on the prospects of Tysabri, half way through a month that could be pivotal in its development, with a response from the FDA on the priority review request (positive would imply that the FDA is satisfied with the data provided) and safety data from the Crohn’s and rheumatoid arthritis patients due. We conclude that: (i) Tysabri against MS will be back in 2006 (we have pulled back 2006 earnings by 14% but moved 2007 forecasts ahead
12.5%); (ii) Tysabri will provide a viable treatment against Crohn’s (despite PML concerns, the current biologic has a more questionable safety profile); and (iii) safety-related changes to the label will have little to no effect on market prospects. Elan’s valuation still hinges on the fate of Tysabri. Our current valuation ranges from $2.88 (ex-Tysabri) to $21.91 (post-PML recovery) - mean of $12.39. With the market only pricing in a limited Tysabri return, the upside implications of a positive response from the FDA to the request for a priority review could see the stock challenging our current price target of $11.15.

[Websman]

HHHmmmmm--Let's see:
ELN's resistance is $8--a triple top of resistance! How pretty in a bear market!
What more--what more I say--what more do you want, Webs, to short this dog?

ELN broke through resistance and closed at $8.10. Who tried to short this dog? lol

[stocks54]

I don't know about you guys but I am starting to lose my patience. I am 50 % invested in Elan (it's a big gamble lot's of call's and LEAPS). I just hope FDA grants priority on sBLA and we get some movement in stock price…

[kingofthehill]

I feel confident we will get a priority review,


here is a very thorough report on Tysabri from Goodbodys research dated Oct. 14th 35 pages!!!

http://www.tixx.com/elan/goodoct2005.pdf

[kingofthehill]

ok nice start to the day $8.45

Elan Corp. (ELN) surged 5.1% in Dublin after it and partner Biogen Idec didn't find any more cases of the fatal PML disease in patients taking its Tysabri drug for Crohn's disease or for rheumatoid arthritis

[stocks54]

I feel confident we will get a priority review,


here is a very thorough report on Tysabri from Goodbodys research dated Oct. 14th 35 pages!!!

http://www.tixx.com/elan/goodoct2005.pdf

Thanks Kingofthehill.

Best Regards,
Stocks54

[spikefader]

King, et al.
Posted charts today in my thread if you want to look.

LOL @ NB's picture. She's a beautiful dog. Allow me to introduce her to my bear

[New-born baby]

ELN's obeying the chart!

NEWS FLASH!

NEWS FLASH!

ELN is falling this morning as per the chart! Spike's short is working!

[kingofthehill]

I really like ELN for the next 10 days...

Priority review comes next week


and drug scripts are written again in December

[Websman]

NEWS FLASH!

NEWS FLASH!

ELN is falling this morning as per the chart! Spike's short is working!

Spike did an excellent job! It might be a good plan to take profits though, before the FDA brings Tysabri back.

[Websman]

Here's an article from the same idiot who printed a false headline about Tysabri. Now he's printing a positive article???



Study lifts prospects for return of Tysabri

Biogen, Elan say no more cases found of rare brain disease

By Jeffrey Krasner, Globe Staff | October 18, 2005

Biogen Idec Inc. of Cambridge and its partner, Elan Corp., yesterday said they have completed a safety review of all the patients who took the multiple sclerosis drug Tysabri and did not find more cases of a rare brain disease that infected three patients.

The news bolstered prospects for Tysabri's return to the market in a limited fashion.

''The overall prognosis has improved for Tysabri," said Ian Sanderson, an analyst with S.G. Cowen Securities in Boston. ''It helps things a little bit."

Biogen Idec and Elan, its Irish partner in the drug, halted sales and dosing of Tysabri in February after one patient died of the disease, called progressive multifocal leukoencephalopathy, and another was suspected of contracting it. Of the three patients confirmed with contracting the disease, two died.

Tysabri was approved last November to treat MS and was on sale for only three months. It was also being tested in patients suffering from rheumatoid arthritis and Crohn's disease, an intestinal ailment. The final part of the review revealed yesterday confirmed there weren't any more cases of PML in the 1,500 patients participating in clinical trials for rheumatoid arthritis and Crohn's disease.

''We're encouraged by the findings of the safety evaluation," said Amy Brockelman, a Biogen Idec spokeswoman. ''There's a significant unmet need in multiple sclerosis, and we hope to bring the product back to patients in need."

The two companies last month submitted a revised marketing plan to the Food and Drug Administration, including changed labeling language. The companies asked for ''accelerated review" of the revised plan.

The FDA has 30 days in which to decide whether it will accelerate the review. If it does, the agency would rule on Tysabri within six months, compared to about a year for standard review.

Sanderson said he believed Tysabri would ultimately generate annual revenue of $400 million to $500 million for the two firms. That is considerably higher than some earlier estimates of how Tysabri might perform if it was again approved for sale, but considerably lower than the billion-dollar blockbuster most anticipated when the drug was introduced.

Elan shares gained 16 cents to close at $8.26, an increase of 2 percent. Biogen Idec gained 61 cents to close at $38.63, an increase of 1.6 percent.

Jeffrey Krasner can be reached at [email protected].

http://www.boston.com/business/globe/articles/2005/10/18/study_lifts_prospects_for_return_of_tysabri/